Cypress Asset Management Inc. TX Buys 1,939 Shares of Johnson & Johnson (NYSE:JNJ)

Cypress Asset Management Inc. TX raised its stake in Johnson & Johnson (NYSE:JNJ) by 4.9% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 41,441 shares of the company’s stock after buying an additional 1,939 shares during the period. Johnson & Johnson makes up 1.9% of Cypress Asset Management Inc. TX’s investment portfolio, making the stock its 11th biggest position. Cypress Asset Management Inc. TX’s holdings in Johnson & Johnson were worth $5,828,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Altshuler Shaham Ltd bought a new position in Johnson & Johnson in the 1st quarter valued at approximately $35,000. Lake Point Wealth Management increased its position in Johnson & Johnson by 144.4% in the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after acquiring an additional 169 shares during the period. SeaBridge Investment Advisors LLC raised its stake in shares of Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares during the last quarter. Lion Street Advisors LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth $45,000. Finally, Joseph P. Lucia & Associates LLC grew its stake in shares of Johnson & Johnson by 50.8% in the first quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock worth $49,000 after purchasing an additional 126 shares during the last quarter. 68.44% of the stock is currently owned by hedge funds and other institutional investors.

JNJ opened at $145.76 on Friday. The company has a fifty day moving average price of $144.04 and a two-hundred day moving average price of $144.14. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00. The company has a market cap of $383.76 billion, a P/E ratio of 21.31, a price-to-earnings-growth ratio of 3.23 and a beta of 0.69. The company has a current ratio of 1.25, a quick ratio of 1.05 and a debt-to-equity ratio of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Thursday, July 16th. The company reported $1.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The company had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. During the same period last year, the business posted $2.58 EPS. The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 7.85 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 2.77%. Johnson & Johnson’s dividend payout ratio is 46.54%.

In related news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares in the company, valued at approximately $3,197,444.54. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.27% of the stock is owned by corporate insiders.

A number of equities research analysts have commented on JNJ shares. SVB Leerink reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Stifel Nicolaus upped their target price on Johnson & Johnson from $140.00 to $155.00 and gave the company a “hold” rating in a report on Wednesday, April 15th. Cantor Fitzgerald reissued a “buy” rating and set a $168.00 target price on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Barclays boosted their price target on shares of Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Finally, Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective for the company. in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and an average price target of $163.38.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: What are the benefits of investing in REITs?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.